Technology developed by 6+ years of research in National University of Singapore.

Platform technology that can adapt to a range of diseases, i.e. Covid-19, Lung cancer, Tuberculosis, etc.

Initial clinical trial has shown over 90% accuracy for Covid-19 detection, and 80% for Lung Cancer detection. 

We are looking to disrupt a USD 55 billion medical diagnostics industry.

Covid-19: Airlines and Checkpoints;
Other fatal diseases: Hospitals and screening centers.

Covid-19 Rapid Mass Screening; Annual Health Screening; Disease diagnostics and management.